Just as demand for coronavirus tests is peaking, the US regulator has a quiet week.
At least two groups have posted early data on T-cell tests for Covid-19; now Qiagen has licensed tech to make its own.
Slower labs are to be paid less for Covid-19 tests, but will the move actually speed things up?
The Covid-19 pandemic has scythed vast sums from joint makers’ Q2 sales. But Medtronic’s summer earnings were better than those for its spring quarter.
Qiagen is one of the few medtechs to do well out of the Covid-19 pandemic. From Thermo Fisher’s point of view it has done too well.
2019 was an average year for medtech M&A. 2020, not so much.
20 key healthcare transactions, most struck before the Covid-19 pandemic hit, have yet to be formally completed.
Despite insisting last year that it was no longer for sale, Qiagen falls to Thermo Fisher for $10bn.
New products and strategic execution buoyed mid and small-cap medtechs, while safety worries took down one former high-flier.